HC Wainwright & Co. Reiterates Buy on Monopar Therapeutics, Maintains $105 Price Target
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $105 price target.
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $105 price target.